Sunday Off the Record with James Altucher

Why they don’t make anything like they used to. September 15, 2024 [WEBSITE]( | [UNSUBSCRIBE]( Rather than focusing on long-term treatments, AI can indeed lead to lasting cures. Here's why. Wasted! CHRIS CAMPBELL Dear Reader, This book, The Waste Makers, first published in 1960, reads like an eerie foreshadowing of our current world… Planned obsolescence, says author Vance Packard, isn't just about making sure your washing machine breaks down right after the warranty expires… It’s also about manipulating entire industries and economies to keep you locked in a cycle of waste and consumption. Packard’s book is loaded with examples of how big industries rigged the system to make sure their products didn’t last. Take the auto industry, where manufacturers like General Motors pioneered a strategy of releasing new car models with purely cosmetic changes year after year. The goal wasn’t to improve the cars—they didn’t need to. It was to make you feel like your perfectly functional vehicle was obsolete. Then there’s the appliance industry—washing machines, refrigerators, all built with inferior parts, guaranteed to break just after a few years. Need a new drum for your washer? Sorry, Jerry. It’s cheaper to just buy a new machine. And don’t forget about the fashion industry, constantly changing trends to ensure that what you wore last season makes you feel like a relic today. Even light bulbs weren’t immune. The Phoebus Cartel - which included General Electric, Philips, and Osram - ensured light bulbs had a limited lifespan of around 1,000 hours, making sure you’d need to replace them more often. Before this agreement, light bulbs had much longer lifespans—some could last up to 2,500 hours or more. Planned obsolescence, perfected. Packard saw all of this in his day and exposed it for what it was: a game rigged against you. (Meanwhile, Austrian economists diagnosed it as a consequence of government intervention distorting market incentives. Probably something.) Fast forward to today… The same strategies that drove consumer goods into obsolescence have quietly taken hold in our healthcare system. But, it’s not always for the reasons most people think. [External Advertisement] [Zero Day Trading Secret Demo]( Every Time the Government Releases Jobs Data... Make This Trade the Night Before! (Target up to 253%... 327%... Even 383% gains... OVERNIGHT!) [Next JOLTS Trade September 15, 2024 at 2 p.m. ET!]( Big Pharma Edition Yes, the monetary incentives are pretty bad. Yes, cures can destroy entire healthcare ecosystems built around managing disease. Yes, management provides ongoing revenue while cures are just breeding one-hitter quitters. However, people also underestimate these things: → The human body is insanely complex. → The R&D costs for cures can be astronomical, with no guarantee of success. → Proving a cure is safe and effective requires longer, more complex clinical trials than proving a treatment is effective. → Most chronic diseases are multifactorial, making most single "silver bullet" cures unlikely. → The risk of failure in developing cures is high, while incremental improvements to existing treatments are often seen as safer bets. So… one of the biggest problems: The technology hasn’t been there. For decades, discovering new drugs was a slow, expensive process, with research and development cycles stretching out over decades and costing billions. Breaking the Cycle: AI as a New Healthcare Model With AI, we have a chance to stop the cycle of planned obsolescence in healthcare. Rather than focusing on long-term treatments, AI can indeed lead to lasting cures. This would change the management-driven system that keeps companies overly risk-averse… To an entire new paradigm of healthcare. Next week, we’re going to cover much more on that front. And reveal some exciting developments. (And how to play it.) Stay tuned and enjoy your weekend, Until next time, Chris Campbell For Altucher Confidential Rate this email Like Dislike Thanks for rating this content! Looks like something went wrong. Please try to rate again. Urgent Notice for {EMAIL} Our records indicate that you ARE NOT currently signed up to receive Monday's time-sensitive trade alert from our company's top trader. This idea could double your money in a single day. Don’t miss this opportunity. [Add your name to our list today](. ☰ ⊗ [UPDATE PREFERENCES]( [Contact Us]( © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](